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Small cell lung cancer (SCLC) responds well to combination
chemotherapy regimens, but although many drugs have been
shown to be active against SCLC, there is no firm evidence that
one particular combination of active drugs is superior to any other
(Murray, 1997) and many different chemotherapy regimens are in
routine use (Ettinger, 1995). In North America, the combination of
cisplatin and etoposide (PE), owing to its lack of severe non-
haematological toxicity, its ease of administration, and the
presumed synergy between the 2 drugs, is said to be widely used
as standard for good prognosis patients (Johnson, 1993), whereas
in Europe, doxorubicin, cyclophosphamide and etoposide (ACE)
is said to be favoured over PE (Groen et al, 1999). It is not known
with any precision, however, which policies are in routine use in
the United Kingdom or which specialists are most commonly
involved in administering chemotherapy to patients with SCLC. 
A survey of clinicians treating lung cancer was therefore under-
taken to establish which chemotherapy regimens are being
prescribed, by whom, and for which prognostic groups of patient.
The findings of this survey would demonstrate whether any
consensus existed on standard chemotherapy and should be useful
in selecting relevant control groups for randomized trials in the
treatment of SCLC and in deciding local treatment policies. 
METHODS 
Target population 
The target population of medical and clinical (radiation) oncolo-
gists, respiratory physicians and general physicians with a special
interest in respiratory medicine was identified from the Royal
College of Physicians’ membership list and from the General
Medical Council’s Specialist Register. The questionnaire was sent
out in August 1998 with a covering letter explaining its aims and
rationale and a stamped addressed envelope. A duplicate question-
naire was sent in January 1999 to non-responders. Those not
replying to this mailing were followed up with a telephone call in
March 1999, which established all those who did not treat SCLC
with chemotherapy. A final mailing was sent in April 1999 to non-
responders and included an additional 64 clinicians who had been
identified from returned questionnaires and from our MRC lung
cancer mailing list. 
The survey 
The survey asked the following questions. 
Part 1: General questions 
Is your status consultant, professor or senior lecturer? If yes please
complete and return the enclosed survey; if no please return the
survey uncompleted. What is your speciality? How many newly
diagnosed SCLC patients do you treat annually? How many of
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chemotherapy regimens do you use for your SCLC patients (e.g.
palliative, intensive etc.)? Do not include regimens used in trials. 
Part 2: Questions about the chemotherapy regimens 
For each chemotherapy regimen indicate the criteria used to define
the subgroup of patients (e.g. performance status, Manchester
Score, age etc.) for which it is used; reasons for this choice, and
number of patients to whom this applies. Do not include patients
whom you see, but refer on without treatment. 
For each regimen: The drugs (please use generic drug names):
Number of cycles. Interval between cycles (weeks). Dose of each
drug (mg/m2). Subgroup of patients (e.g. performance status, age,
extent of disease etc.) Reasons (please tick one or more): patient
convenience (toxicity:efficacy ratio); trial results (which trial(s)?);
cost; quality of life benefits; standard local routine protocol; other
(specify). In addition there was a space for comments. 
No information was requested about thoracic radiotherapy or
prophylactic cranial irradiation. 
Measures of performance status and prognosis 
The WHO performance status (World Health Organization, 1979)
or the prognostic scoring system, the Manchester score (Cerny 
et al, 1987), was used by some respondents or was derived from
their responses. The WHO grades are: 0 = able to carry out all
normal activity without restriction; 1 = restricted in physically
strenuous activity but ambulatory and able to carry out light work;
2 = ambulatory and capable of all self-care but unable to carry out
any work; up and about more than 50% of waking hours; 3 =
capable of only limited self-care; confined to bed or chair more
than 50% of waking hours; 4 = completely disabled; cannot carry
out any self-care; totally confined to bed or chair. The Manchester
score is derived from pretreatment factors as follows: 0 = starting
score; +1 if lactate dehydrogenase >450 U l–1 (upper normal limit);
+1 if extensive stage; +1 if serum sodium <132 mmol l–1; +1 if
Karnofsky score <60; +1 if alkaline phosphatase >165 U l–1 (1.5-
fold upper limit); +1 if serum bicarbonate <24 mmol l–1. The range
of possible scores is 0–6. 
RESULTS 
Consultants giving chemotherapy 
A total of 1214 questionnaires were sent out and responses were
obtained from 1070 clinicians, giving a compliance rate of 88%.
777 of the 1070 respondents did not treat SCLC with chemotherapy;
an additional 27 did give chemotherapy, but had their caseload
included in the questionnaire answered by another member of their
department. Of the 266 consultants who did give chemotherapy,
54 (20%) were medical oncologists, 112 (42%) clinical oncolo-
gists, 76 (29%) respiratory physicians, and 24 (9%) general physi-
cians. Of an estimated 7724 SCLC patients treated annually, 4674
(61%) were given chemotherapy. 1695 (36%) of the 4674 given
chemotherapy were treated by clinical oncologists, 1400 (30%) by
medical oncologists, 1262 (27%) by respiratory physicians, and
317 (7%) by general physicians. Overall, 34 different regimens
were used, with a total of 151 different combinations of dose and
schedule. The acronyms of all the regimens are listed in Table 1. 
Prognostic groups 
Patients were placed into broad prognostic groups on the basis of
the criteria clinicians used to select chemotherapy regimens. These
groups are shown in Table 2, along with the number of patients
included in each group. There is inevitably a slight overlap
between some of the groups (e.g. the good and the poor prognostic
groups in patients with a WHO performance status of 2) because
prognostic groups were not defined in the survey but left to
respondents. Moreover, some clinicians chose treatment purely on
the basis of extent of disease, with no reference to performance
status or other prognostic factors, and some did not assign patients
to prognostic groups at all or did not specify any prognostic
criteria. The good performance status group includes all patients
with a Manchester score of 0 or 1, whatever the extent of their
disease. The poor performance status group encompasses patients
with a Manchester score of 2 or more, whatever the extent of their
disease. The miscellaneous groups were mainly accounted for by
patients with co-morbidity. The other groups are self-explanatory,
although it should be noted that we did not ask for information on
second-line treatment. 
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Table 1 Acronyms for the chemotherapy regimens 
Acronym Drugs 
Platinum-based regimens
CbE Carboplatin, etoposide 
CbEV Carboplatin, etoposide, vincristine 
ChEP Chlorambucil, etoposide, cisplatin 
GP Gemcitabine, cisplatin 
ICbE Ifosfamide, carboplatin, etoposide 
IPE Ifosfamide, cisplatin, etoposide 
MIP Mitomycin, ifosfamide, cisplatin 
MVbP Mitomycin, vinblastine, cisplatin 
NP Vinorelbine, cisplatin 
PE Cisplatin, etoposide 
PET Cisplatin, etoposide, paclitaxel 
VICbE Vincristine, ifosfamide, carboplatin, etoposide 
Doxorubicin-based regimens
ACE Doxorubicin, cyclophosphamide, etoposide 
AVE Doxorubicin, vincristine, etoposide 
AVI Doxorubicin, vincristine, ifosfamide 
CAV Cyclophosphamide, doxorubicin, vincristine 
CAVb Cyclophosphamide, doxorubicin, vinblastine 
CAV/PE Cyclophosphamide, doxorubicin, vincristine
alternating with PE 
CAVE Cyclophosphamide, doxorubicin, vincristine,
etoposide 
Other multi-drug regimens
CEpV Cyclophosphamide, epirubicin, vincristine 
CE Cyclophosphamide, etoposide 
CEV Cyclophosphamide, etoposide, vincristine 
ECMxV Etoposide, cyclophosphamide, methotrexate,
vincristine 
ChPrPdE Chlorambucil, procarbazine, prednisolone,
etoposide 
CVLMx Cyclophosphamide, vincristine, lomustine,
methotrexate 
EpEC Epirubicin, etoposide, cyclophosphamide 
EV Etoposide, vincristine 
EVEp Etoposide, vincristine, epirubicin 
VIE Vincristine, ifosfamide, etoposide 
VnE Vindesine, etoposide 
Single-drug regimens
C Cyclophosphamide 
Oral E Oral etoposide 
Ep Epirubicin 
Cb Carboplatin Regimens prescribed for patients with good prognosis 
Table 3 shows the regimens prescribed for patients with good
performance status and for those classified solely on the basis of
their having limited disease. Both these groups were regarded as
having relatively good prognosis and we have therefore combined
them in the table. 23 regimens were reported; those most
frequently used are shown, ranked, in the table. Of the 9 most
frequently prescribed, 4 were platinum-based (ICbE, CbE, PE,
VICbE), 4 doxorubicin-based (ACE, CAV, CAV/PE, CAVE;
CAV/PE also containing cisplatin), and the ninth (ECMxV)
contained neither platinum nor doxorubicin. 
There was substantial variation in the drug dosages used. For
example, in the ACE regimen, the most commonly prescribed
regimen, the dose of doxorubicin ranged from 30–60 mg m–2, the
dose of cyclophosphamide from 600–1000 mg m–2, and the dose of
etoposide from 100–150 mg m–2 i.v. The most frequently used
combination of doses was doxorubicin 40–60 mg m–2, cyclophos-
phamide 1000 mg m–2, and i.v. etoposide 120 mg m–2. Similar vari-
ation was seen in the other regimens. The number of cycles of
chemotherapy prescribed for this group of patients ranged from
3–6, regardless of regimen, 6 being prescribed for 85% of the
patients. 
Regimens prescribed for patients with poor prognosis 
Table 4 shows the regimens prescribed for patients with poor
performance status and for those classified solely on the basis of
their having extensive disease. Both these groups were regarded as
having relatively poor prognosis and we have therefore combined
them in the table. 21 regimens were reported; the most frequently
used are shown, ranked, in the table. Of the 10 most frequently
prescribed, 2 were platinum-based (CbE, Cb), 4 doxorubicin-
based (CAV, CAV/PE, CAVE, ACE; CAV/PE also containing
cisplatin), and 4 contained neither platinum nor doxorubicin (EV,
Oral E, CE, VIE). Two were single-drug regimens (Oral E, Cb). 
There was substantial variation in drug dosages. In the CAV
regimen, the most frequently prescribed regimen, the dose of
cyclophosphamide ranged from 500–1000 mg m–2, the dose 
of doxorubicin from 35–60 mg m–2 and the dose of vincristine
from 1–2 mg m–2. The most frequently used combination of doses
was cyclophosphamide 750 mg m–2, doxorubicin 40 mg m–2 and
vincristine 1.3 mg m–2. Similar variation was seen in the other regi-
mens. The number of cycles of chemotherapy prescribed for this
group of patients ranged from 2–6, regardless of regimen, 6 being
prescribed for 61% of the patients and 4 for 31%. 
Regimens prescribed for other patient groups 
Among the other groups of patients (Table 2), the distinguishing
feature of regimens chosen for the 47 patients with cardiac prob-
lems (17 with good performance status, 30 with poor performance
status), was that they did not contain doxorubicin; the commonest
regimens were CAV, CbE, EV and PE. For the 118 patients classi-
fied as including all except the very fit, and the 334 who were not
grouped by prognosis, the commonest regimens were CAV, CbE,
CAVE and CAV/PE. The commonest regimens for the 70 patients
in miscellaneous groups were CbE, CAV and E. Information on
second-line regimens was not requested and so data on these will
be incomplete. 
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Table 2 Prognostic groups derived from the survey responses and number
of patients in each group 
Patients 
Prognostic groupa No. % 
Good PS (WHO 0–2), any stage, MS 0–1 2262  48 
Limited disease, not otherwise defined 49 1 
Good PS but with cardiac problems 17 <1 
Poor PS (WHO 2–4), any stage, MS 2–6 1406  30 
Extensive disease, not otherwise defined 111 2 
Poor PS with cardiac problems 30 1 
All patients except very fit 118 3 
Ungrouped for prognosis 334 7 
Second-line chemotherapy for relapse 58 1 
Other miscellaneous groups 70 1 
No prognostic criteria specified 219 5 
Total patients 4674 100 
aPS = performance status; MS = Manchester score. 
Table 3 Commonest of 23 regimens prescribed for 2262 patients with good
performance status and 49 with limited disease 
Patients 
Regimena No. % 
ACE 640 28 
ICbE 288 13 
CAV 283 12 
CbE 277 12 
PE 275 12 
CAV/PE 197 9 
CAVE 183 8 
VICbE 36 2 
ECMxV 23 1 
Other regimensb 109 5 
Total patients 2311 100 
aFor definitions, see Table 1.bOther regimens, each accounting for less than
1% of patients were, in order of frequency, MIP, AVE, MVbP, NP, AVI, E, IPE,
CbEV, EpEC, CEpV, CE, CEV, EV, and PET. 
Table 4 Commonest of 21 regimens prescribed for 1406 patients with poor
performance status and 111 with extensive disease 
Patients 
Regimena No. % 
CAV 544 36 
EV 264 17 
CbE 137 9 
CAV/PE 136 9 
Oral E 132 9 
CAVE 88 6 
ACE 50 3 
CE 41 3 
Cb 29 2 
VIE 25 2 
Other regimensb 71 5 
Total patients 1517 100 
aFor definitions, see Table 1.bOther regimens, each accounting for less than
1% of patients were, in order of frequency, ChEP, EpEC, Ep, EVEp, PE,
CEpV, MVbP, AVI, CbEV, CEV, and ECMxV. Single-drug chemotherapy 
Single-drug chemotherapy was given to a total of 228 patients (5%
of all patients given chemotherapy). Of these 228 patients, 166
received oral etoposide, 51 carboplatin, 10 epirubicin and 1
cyclophosphamide. Single-drug chemotherapy was given almost
exclusively to poor performance status patients, for urgent pallia-
tion, or as second-line treatment. 
Reasons for choice of regimen 
The reasons consultants gave for their choice of regimens (Table
5) varied according to regimen. The table shows for the 5 most
commonly prescribed regimens in each of the good and poor prog-
nosis groups, the number of consultants using each regimen, the
number of patients affected, and the percentage of consultants
influenced by each reason for choice of regimen. 
For patients with good prognosis (upper part of table), treatment
according to a standard local routine protocol was the single most
frequently stated reason, but patient convenience also influenced
choice substantially, particularly for CAV and CbE. Trial results
were influential, especially in the choice of ICbE. Quality of life
benefits had some influence for all 5 regimens; cost was the least
frequently quoted reason for choice of regimen. 
For patients with poor prognosis (lower part of the table), CAV,
EV and Oral E were used by substantially more consultants than
were CbE and CAV/PE. Treatment according to a standard local
routine protocol and patient convenience were again important
reasons. Patient convenience was influential for 9 of the 10 consul-
tants prescribing CbE, as were quality of life benefits. Cost was,
again, the least frequently reported reason for choice of regimen. 
DISCUSSION 
The high level of compliance by clinicians in responding to this
survey suggests that they considered the questions clinically
important and the findings potentially interesting. The reliability
of the results of such surveys is bound to depend, in part, on the
compliance rates achieved. If a survey is perceived as addressing
important issues, good compliance should be the aim and should
be expectantly pursued. It is essential to explain to those surveyed
the reasons for conducting a survey and why the findings are likely
to prove important. 
In the present survey, clinical (i.e. radiation) oncologists were
the specialists most involved in giving chemotherapy. The others,
in order of the number of patients treated with chemotherapy, were
medical oncologists, respiratory physicians, and general physi-
cians with a special interest in respiratory disease. The major
involvement of clinical oncologists can almost certainly be
explained by the small number of medical oncologists in this
country and the large number of patients requiring treatment. It is
important that all specialists giving chemotherapy are trained to do
so, and have available the necessary oncology trained staff and
facilities. According to the recently published Guidance on
Commissioning Cancer Services: Improving Outcomes in Lung
Cancer (NHS Executive, 1998), chemotherapy should be given in
units or centres where close supervision by oncologists and
chemotherapy nurse specialists, expert pharmacy and 24-hour
laboratory support are available. Patients receiving chemotherapy
should have access to emergency care, information and advice
from oncology trained staff on a 24-hour basis. It is particularly
important to ensure that these requirements are met when
chemotherapy is being given within a number of different clinical
specialities. 
A wide variety of chemotherapy regimens is being used to treat
small cell lung cancer. This variety is partly to be expected
because different regimens are appropriate for different groups of
patients. The fittest are typically those with good performance
status, limited disease, no major symptoms, little if any co-
morbidity, and able to tolerate intensive chemotherapy and high-
dose thoracic radiotherapy given with curative intent. At the other
end of the range are people with poor performance status, exten-
sive disease, major symptoms, major co-morbidity, and only able
to tolerate relatively non-toxic, palliative treatment aimed at
controlling their symptoms, improving their quality of life,
prolonging survival and keeping them at home as much as
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Table 5 Reasons given by consultants for choice of the most commonly prescribed regimens 
Patients with good prognosis 
Regimen ACE ICbE CAV CbE PE 
Number of consultants 60 35 26 26  31 
Number of patients 640 288 283 277  275 
Reason for choice (% consultants) 
Patient convenience 43% 29% 81%  69% 29% 
Trial results 32% 71% 50% 23% 26% 
Cost 18% 0% 46% 8% 14% 
Quality of life benefits 25% 37% 46% 43% 29% 
Standard local routine protocol 77% 57%  69% 73% 57% 
Patients with poor prognosis 
Regimen CAV EV CbE CAV/PE Oral E 
Number of consultants 63 36 10 10  37 
Number of patients 544 264 137 136  132 
Reason for choice (% consultants) 
Patient convenience 49% 67% 90%  30% 57% 
Trial results 43% 69% 10% 50%  3% 
Cost 24% 19% 10% 20% 5% 
Quality of life benefits 37% 56% 90% 20% 57% 
Standard local routine protocol 60% 61%  60% 60% 41% possible. The survey has, however, revealed great variety within
prognostic groups of patients, suggesting much uncertainty about
which regimens are considered to confer the greatest benefits in
terms of survival and quality of life. There is clearly no general
agreement that one chemotherapy regimen, or one of a small group
of regimens, should be regarded as standard treatment. 
This multiplicity of standard regimens has come about because no
large randomized trial has confirmed the superiority of one over any
other of as many as a dozen different combination chemotherapy
regimens. This is reflected in the above-mentioned NHS Executive
document which states that no regimen has been shown to be clearly
superior to a variety of combinations (usually between 2 and 4) of
the following drugs: cyclophosphamide, doxorubicin, vincristine,
etoposide, cisplatin/carboplatin, ifosfamide. 
In all, 23 regimens were used to treat patients with relatively good
prognosis. The 9 most commonly used regimens accounted for 95%
of these patients, but they varied greatly in the drugs they contained,
and platinum drugs were clearly not considered essential. In
currently open randomized trials in the United Kingdom, regimens
in use as standard control regimens include ACE and PE by the
Medical Research Council, and CAV/PE by the London Lung
Cancer Group. In North America, PE is widely regarded as standard
(Murray 1997), while ACE is considered standard by the European
Organization for Research and Treatment of Cancer (Groen et al,
1999). The Textbook of Lung Cancer recently published by the
International Association for the Study of Lung Cancer (IASLC)
lists the following regimens as commonly used and, by implication,
standard: PE, CAV, ACE, and CbE (Carney and Shepherd, 2000). 
For patients with poor prognosis, 21 regimens were used, the 10
most frequently used accounting for 95% of the patients. Among
these 10, 5 (CAV, CbE, CAV/PE, CAVE, ACE) were also among the
9 most commonly used to treat patients with good prognosis. There
still seems to be a role for some single agents which have been
shown to be inferior to multi-drug regimens, in terms of quality of
life or survival or both. Oral etoposide on its own, for example, was
used in 9% of patients with poor performance status, despite the
proven superiority of intravenous combinations (CAV or EV) and
the higher risk of haematological toxicity with oral etoposide in this
group of patients (Medical Research Council Lung Cancer Working
Party, 1996; Souhami et al, 1997). Both the NHS Executive 
document and the IASLC textbook recommend combination
chemotherapy in this group of patients. 
The most commonly used regimens: ACE, ICbE, CAV and Cb(or
P)E for patients with relatively good prognosis, and CAV, EV, CbE
and CAV/PE for patients with poor prognosis, seem reasonable
choices. There was wide variation, however, in the dosages
prescribed. Such variation is of particular concern in patients with
relatively good prognosis, in whom an important aim of treatment is
to prolong survival and achieve cure in some patients. Arriagada and
colleagues (1993) found that giving higher doses of cyclophos-
phamide and cisplatin for just the first cycle of a 6-cycle regimen
improved survival. The best dosages in terms of survival benefits
and acceptable toxicity need to be defined for commonly used regi-
mens so that the best outcomes can be achieved in routine practice. 
The most commonly used regimens included both platinum-
based and doxorubicin-based drug combinations. A meta-analysis
of published data from 4054 evaluable patients in 19 randomized
trials comparing a cisplatin-containing regimen versus a non-
platinum regimen investigated survival, response and toxicity
(Pujol et al, 2000). It showed that a cisplatin-containing regimen
yielded a higher response rate and probability of survival than did
a regimen containing other alkylating agents without a perceptible
increase in risk of toxic death. No direct comparison was made,
however, between platinum-based and doxorubicin-based regi-
mens. Further research is needed to determine the most active and
most acceptable drug combinations in the treatment of small cell
lung cancer. 
The great majority of patients with relatively good prognosis
were prescribed 6 cycles of chemotherapy, and of those with poor
prognosis 4 or 6 cycles. This is in keeping with findings from a
number of randomized trials that investigated duration of
chemotherapy (Cullen et al, 1986; Medical Research Council
Lung Cancer Working Party, 1989, 1993; Spiro et al, 1989;
Giaconne et al, 1993). 
A Medical Research Council Lung Cancer Working Party trial
has shown that in the treatment of patients with good performance
status, increasing the dose-intensity of ACE chemotherapy by
means of granulocyte colony-stimulating factor support improved
survival while maintaining acceptable toxicity (Thatcher et al,
2000). Further research is needed to establish whether similar
improvements can be achieved with other regimens, or whether
other strategies, such as concurrent multiple-daily-fraction radio-
therapy and PE chemotherapy (Turrisi et al, 1999) would be
preferable. 
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